Immortal Dragons, a US$40 million purpose-driven longevity fund based in Singapore, has announced a strategic investment in Frontier Bio, a biotechnology company focused on 3D biofabrication leveraging stem cells, organ-on-a-chip systems and perfusion bioreactor technology, according to the company. The fund’s support targets Frontier Bio’s development of functional blood vessels and complex tissue platforms with applications in vascular grafting and pre-clinical testing.
The company said that its engineered blood vessels address critical unmet needs in a market estimated to exceed US$12 billion annually, where synthetic alternatives can have failure rates as high as 65 percent. According to the company, its vascular grafts demonstrated in large animal studies that they remained patent without thrombosis or infection for 14 days, while supporting cell infiltration, endothelial formation and integration with surrounding tissue.
Frontier Bio claims its products offer several advantages over both autologous vessels and conventional synthetic grafts, including off-the-shelf availability, suitability for small-diameter vessels, cellularization at implantation and the ability to form complex geometries. The company also develops organ-on-a-chip models—such as in-vitro blood-brain barrier and mini-lung platforms—designed to improve pre-clinical trial accuracy compared to animal models.
Immortal Dragons said the investment aligns with its longevity mission, targeting the US$150 billion organ transplant market and supporting on-demand organ and tissue replacement technologies. The company said Frontier Bio’s bioprinting platform also enables applications such as artificial womb development through creation of vascular networks and specialized tissues.
